Movatterモバイル変換

[0]ホーム
URL:

WO2022069579A3 - Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers - Google Patents

Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersDownload PDF

Info

Publication number
WO2022069579A3
WO2022069579A3PCT/EP2021/076848EP2021076848WWO2022069579A3WO 2022069579 A3WO2022069579 A3WO 2022069579A3EP 2021076848 WEP2021076848 WEP 2021076848WWO 2022069579 A3WO2022069579 A3WO 2022069579A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
cancers
different types
against different
immunotherapy against
Prior art date
Application number
PCT/EP2021/076848
Other languages
French (fr)
Other versions
WO2022069579A2 (en
Inventor
Jens Hukelmann
Heiko Schuster
Lena Wullkopf
Christoph Schräder
Jens Fritsche
Daniel Kowalewski
Michael Römer
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102020125465.2Aexternal-prioritypatent/DE102020125465A1/en
Priority to KR1020237013847ApriorityCriticalpatent/KR20230079121A/en
Priority to AU2021352111Aprioritypatent/AU2021352111A1/en
Priority to CA3193567Aprioritypatent/CA3193567A1/en
Priority to CN202180080197.2Aprioritypatent/CN116724048A/en
Priority to JP2023518954Aprioritypatent/JP2023542998A/en
Application filed by Immatics Biotechnologies GmbhfiledCriticalImmatics Biotechnologies Gmbh
Priority to EP21785884.4Aprioritypatent/EP4221741A2/en
Priority to IL301444Aprioritypatent/IL301444A/en
Publication of WO2022069579A2publicationCriticalpatent/WO2022069579A2/en
Publication of WO2022069579A3publicationCriticalpatent/WO2022069579A3/en
Anticipated expirationlegal-statusCritical
Ceasedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
PCT/EP2021/0768482020-09-292021-09-29Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersCeasedWO2022069579A2 (en)

Priority Applications (7)

Application NumberPriority DateFiling DateTitle
IL301444AIL301444A (en)2020-09-292021-09-29 Amidated peptides and their deamidated copies are shown on NON-HLA-A 02 for use in immunotherapy against various types of cancer
AU2021352111AAU2021352111A1 (en)2020-09-292021-09-29Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
CA3193567ACA3193567A1 (en)2020-09-292021-09-29Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
CN202180080197.2ACN116724048A (en)2020-09-292021-09-29Amidated peptides displayed by non-HLA-A-02 for immunotherapy of different types of cancers and deamidated counterparts thereof
JP2023518954AJP2023542998A (en)2020-09-292021-09-29 Amidated peptides presented by non-HLA-A*02 and their deamidated counterparts for use in immunotherapy against various types of cancer
KR1020237013847AKR20230079121A (en)2020-09-292021-09-29 Amidated peptides displayed by non-HLA-A*02 and their deamidated counterparts for use in immunotherapy for different types of cancer
EP21785884.4AEP4221741A2 (en)2020-09-292021-09-29Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
US202063084919P2020-09-292020-09-29
DE102020125465.2ADE102020125465A1 (en)2020-09-292020-09-29 Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer
DE102020125465.22020-09-29
US63/084,9192020-09-29
US202163223291P2021-07-192021-07-19
US63/223,2912021-07-19

Publications (2)

Publication NumberPublication Date
WO2022069579A2 WO2022069579A2 (en)2022-04-07
WO2022069579A3true WO2022069579A3 (en)2022-07-07

Family

ID=78049255

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/EP2021/076848CeasedWO2022069579A2 (en)2020-09-292021-09-29Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers

Country Status (8)

CountryLink
EP (1)EP4221741A2 (en)
JP (1)JP2023542998A (en)
KR (1)KR20230079121A (en)
AU (1)AU2021352111A1 (en)
CA (1)CA3193567A1 (en)
IL (1)IL301444A (en)
TW (1)TW202229312A (en)
WO (1)WO2022069579A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20070020327A1 (en)*1998-11-102007-01-25John FikesInducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2010037395A2 (en)*2008-10-012010-04-08Dako Denmark A/SMhc multimers in cancer vaccines and immune monitoring

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4440859A (en)1977-05-271984-04-03The Regents Of The University Of CaliforniaMethod for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)1977-11-081987-11-03Genentech, Inc.Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (en)1978-12-221997-04-14Biogen Inc Recombinant hepatitis B virus DNA molecules, host organisms transformed therewith, HBV antigen-specific polypeptides, DNA sequences encoding HBV antigen-specific polypeptides, methods for detecting hepatitis B virus antibodies, methods for producing said DNA molecules, methods for producing said polypeptides and agents for detecting HBV infection
US4530901A (en)1980-01-081985-07-23Biogen N.V.Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)1980-02-221982-08-03Scripps Clinic & Research FoundationSolid phase anti-C3 assay for detection of immune complexes
US4678751A (en)1981-09-251987-07-07Genentech, Inc.Hybrid human leukocyte interferons
US4766075A (en)1982-07-141988-08-23Genentech, Inc.Human tissue plasminogen activator
US4582800A (en)1982-07-121986-04-15Hoffmann-La Roche Inc.Novel vectors and method for controlling interferon expression
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US4757006A (en)1983-10-281988-07-12Genetics Institute, Inc.Human factor VIII:C gene and recombinant methods for production
EP0173494A3 (en)1984-08-271987-11-25The Board Of Trustees Of The Leland Stanford Junior UniversityChimeric receptors by dna splicing and expression
GB8422238D0 (en)1984-09-031984-10-10Neuberger M SChimeric proteins
US4677063A (en)1985-05-021987-06-30Cetus CorporationHuman tumor necrosis factor
JPS61134325A (en)1984-12-041986-06-21Teijin LtdExpression of hybrid antibody gene
US4810648A (en)1986-01-081989-03-07Rhone Poulenc AgrochimieHaloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)1986-06-271990-01-30The Administrators Of The Tulane Educational FundMethod for synthesizing a peptide containing a non-peptide bond
US6407213B1 (en)1991-06-142002-06-18Genentech, Inc.Method for making humanized antibodies
WO1993008829A1 (en)1991-11-041993-05-13The Regents Of The University Of CaliforniaCompositions that mediate killing of hiv-infected cells
WO1994021293A1 (en)1993-03-191994-09-29Duke UniversityMethod of treatment of tumors with an antibody binding to tenascin
EP0916678A3 (en)1993-06-031999-05-26Therapeutic Antibodies Inc.Method of clotting blood
AUPM322393A0 (en)1993-12-241994-01-27Austin Research Institute, TheMucin carbohydrate compounds and their use in immunotherapy
CA2207869A1 (en)1994-12-021996-06-06Chiron CorporationMethod of promoting an immune response with a bispecific antibody
US5837234A (en)1995-06-071998-11-17Cytotherapeutics, Inc.Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
AU1394497A (en)1996-01-171997-08-11Imperial College Innovations LimitedImmunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en)1996-03-111998-12-15Duke UniversityCulturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5922845A (en)1996-07-111999-07-13Medarex, Inc.Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6653104B2 (en)1996-10-172003-11-25Immunomedics, Inc.Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6406705B1 (en)1997-03-102002-06-18University Of Iowa Research FoundationUse of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE472601T1 (en)2000-03-272010-07-15Technion Res And Dev Of Founda CLASS I SINGLE-CHAIN MAIN HISTOCOMPATIBILITY COMPLEXES (MHC-I), CODING CONSTRUCTS AND METHODS OF THEIR GENERATION
US20040191260A1 (en)2003-03-262004-09-30Technion Research & Development Foundation Ltd.Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1289564B1 (en)2000-06-052018-07-18Altor BioScience CorporationT cell receptor fusions and conjugates and methods of use thereof
ES2727425T3 (en)2000-12-122019-10-16Medimmune Llc Molecules with prolonged half-lives, compositions and uses thereof
US6992176B2 (en)2002-02-132006-01-31Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en)2002-02-202003-08-28Dyax Corp.Mhc-peptide complex binding ligands
AU2003271904B2 (en)2002-10-092009-03-05Adaptimmune LimitedSingle chain recombinant T cell receptors
AU2003276403B2 (en)2002-11-092010-04-15Adaptimmune LimitedT cell receptor display
GB0304068D0 (en)2003-02-222003-03-26Avidex LtdSubstances
KR20070039911A (en)2004-06-012007-04-13도만티스 리미티드 Bispecific Fusion Antibodies with Enhanced Serum Half-Life
US8367805B2 (en)2004-11-122013-02-05Xencor, Inc.Fc variants with altered binding to FcRn
WO2009085462A1 (en)2007-12-192009-07-09Centocor, Inc.Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US20090263574A1 (en)2008-04-212009-10-22Quinn Daniel EMethod of restoring an article
US9840695B2 (en)2009-04-282017-12-12Agriculture Victoria Services Pty LtdPlant technology
GB201006360D0 (en)2010-04-162010-06-02Immatics Biotechnologies GmbhMethod for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (en)2010-10-262012-05-03Technion Research & Development Foundation Ltd.Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en)2011-10-192013-04-25Oslo Universitetssykehus HfCompositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en)2012-11-082014-05-15Roche Diagnostics GmbhNucleic acids encoding chimeric polypeptides for library screening
US20140308285A1 (en)2013-03-152014-10-16Amgen Inc.Heterodimeric bispecific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20070020327A1 (en)*1998-11-102007-01-25John FikesInducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2010037395A2 (en)*2008-10-012010-04-08Dako Denmark A/SMhc multimers in cancer vaccines and immune monitoring

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALTRICH-VANLITH MICHELLE L. ET AL: "Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N -Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases", THE JOURNAL OF IMMUNOLOGY, vol. 177, no. 8, 15 October 2006 (2006-10-15), US, pages 5440 - 5450, XP055884236, ISSN: 0022-1767, Retrieved from the Internet <URL:https://www.jimmunol.org/content/jimmunol/177/8/5440.full.pdf> DOI: 10.4049/jimmunol.177.8.5440*
MEI SHUTAO ET AL: "Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors", MOLECULAR & CELLULAR PROTEOMICS, vol. 19, no. 7, 1 May 2020 (2020-05-01), US, pages 1236 - 1247, XP055883978, ISSN: 1535-9476, DOI: 10.1074/mcp.RA119.001846*

Also Published As

Publication numberPublication date
EP4221741A2 (en)2023-08-09
CA3193567A1 (en)2022-04-07
IL301444A (en)2023-05-01
AU2021352111A1 (en)2023-05-04
KR20230079121A (en)2023-06-05
JP2023542998A (en)2023-10-12
WO2022069579A2 (en)2022-04-07
TW202229312A (en)2022-08-01

Similar Documents

PublicationPublication DateTitle
EP2594582A3 (en)Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
NZ624533A (en)Novel immunotherapy against several tumors including neuronal and brain tumors
US10647742B2 (en)Method for synthesizing etelcalcetide
NZ606427A (en)Extended recombinant polypeptides and compositions comprising same
EP2476697A3 (en)Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
CA3073806A1 (en)Opioid agonist peptides and uses thereof
DK2162462T3 (en) CXC-CHEMOKIN RECEPTOR-4 (CXCR4) ANTAGONISTIC POLYPEPTIDE
JP2017522362A5 (en)
RU2015103816A (en) CELLING PEPTIDES IN THE CELL, THE TARGET OF WHICH IS THE eIF4E
AU2021224412A1 (en)Human transferrin receptor binding peptide
IL195831A0 (en)Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same
WO2011135222A3 (en)Use of peptides as transporters intended for the internalization of molecules of interest into target cells
EP2481748A3 (en)Foxp3 peptide vaccine
CN110461861A (en) Preparation and utilization of ginseng peptides and ginseng peptide-like peptides
JP2013523084A5 (en)
RU2012136464A (en) MELK MODIFIED PEPTIDES AND THEIR VACCINES CONTAINING THEM
WO2020150313A1 (en)Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens
WO2022069579A3 (en)Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
NZ603611A (en)Insulin-like growth factor 1 receptor binding peptides
WO2022069557A3 (en)Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers
NZ591133A (en)Novel melanoma antigen peptide and uses thereof
RU2011130796A (en) C1ORF59 PEPTIDES AND THEIR VACCINES CONTAINING THEM
JP2014506114A5 (en)
RU2011140168A (en) VANGL1 PEPTIDES AND THEIR VACCINES CONTAINING THEM
NZ603379A (en)Ect2 peptides and vaccines including the same

Legal Events

DateCodeTitleDescription
WWEWipo information: entry into national phase

Ref document number:AU2021352111

Country of ref document:AU

ENPEntry into the national phase

Ref document number:3193567

Country of ref document:CA

ENPEntry into the national phase

Ref document number:2023518954

Country of ref document:JP

Kind code of ref document:A

ENPEntry into the national phase

Ref document number:20237013847

Country of ref document:KR

Kind code of ref document:A

WWEWipo information: entry into national phase

Ref document number:202347030735

Country of ref document:IN

NENPNon-entry into the national phase

Ref country code:DE

ENPEntry into the national phase

Ref document number:2021352111

Country of ref document:AU

Date of ref document:20210929

Kind code of ref document:A

ENPEntry into the national phase

Ref document number:2021785884

Country of ref document:EP

Effective date:20230502

WWEWipo information: entry into national phase

Ref document number:202180080197.2

Country of ref document:CN

121Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number:21785884

Country of ref document:EP

Kind code of ref document:A2

WWWWipo information: withdrawn in national office

Ref document number:301444

Country of ref document:IL
[8]ページ先頭
©2009-2025 Movatter.jp